Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have earned an average rating of “Moderate Buy” from the eleven ratings firms that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $101.8571.

Several equities research analysts have recently commented on the company. Weiss Ratings restated a “hold (c)” rating on shares of Lantheus in a report on Tuesday, May 26th. B. Riley Financial restated a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. The Goldman Sachs Group restated a “neutral” rating and set a $94.00 price target on shares of Lantheus in a research note on Thursday, May 7th. Mizuho boosted their price target on shares of Lantheus from $100.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. Finally, Jefferies Financial Group restated a “buy” rating and set a $110.00 price target on shares of Lantheus in a research note on Tuesday, March 17th.

Lantheus Stock Performance

Shares of LNTH stock opened at $102.82 on Friday. The company has a market cap of $6.69 billion, a price-to-earnings ratio of 24.78 and a beta of -0.03. Lantheus has a 52 week low of $47.25 and a 52 week high of $103.89. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. The firm has a 50 day moving average of $87.50 and a 200-day moving average of $74.77.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping the consensus estimate of $1.25 by $0.21. The company had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The company’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, equities analysts forecast that Lantheus will post 4.41 earnings per share for the current year.

Hedge Funds Weigh In On Lantheus

Large investors have recently added to or reduced their stakes in the business. Western Wealth Management LLC purchased a new stake in shares of Lantheus in the first quarter worth approximately $25,000. Osterweis Capital Management Inc. purchased a new stake in shares of Lantheus in the second quarter worth approximately $36,000. Hantz Financial Services Inc. raised its stake in shares of Lantheus by 412.5% in the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 396 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares during the last quarter. Finally, Bessemer Group Inc. raised its stake in shares of Lantheus by 221.3% in the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 354 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.